Divis Laboratories Ltd
Divis Laboratories Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #52 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years. Divi's Laboratories anticipates positive growth in the next 1-2 years driven by new product launches, especially generics coming off patents, and growth in contract synthesis (CS) business (Pages 9, 16).
From Divis Laboratories Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years.
- Revenue growth driven by a mix of generic and custom synthesis (CS) businesses; CS currently contributing a larger share (~55%).
- New generics coming off patent are expected to add volume and revenue.
- Custom synthesis business growth supported by advancing projects, including peptides and late-life cycle management; three major capex programs underway to expand capacity.
- Peptide segment showing strong momentum with investments scaling up alongside customer regulatory progress.
- Nutraceutical business is evolving as a key growth driver.
2 more points from Divis Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Divis Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Divi's Laboratories is executing three major capex programs focused on new technologies, capacity expansion, and key strategic projects.
- Capex is strategically planned and spread across all three production units, not concentrated in one.
- Capex guidance for FY26 was initially ₹2,000 crores, with ₹1,550 crores spent in H1; FY26 capex expected to be higher than ₹2,000 crores.
- Further investments will be aligned with long-term contracts and regulatory approvals, expected to start contributing revenues in 1-2 years.
- Ongoing construction of production blocks in Unit 3 for key starting materials; additional blocks to be built as needed on available land.
2 more points from Divis Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Divis Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a strong and healthy pipeline of projects currently in various phases, including equipment installation, qualification, and validation.
- Revenues from the announced projects are expected to begin entering the books within the next 1 to 2 years, subject to regulatory approvals.
- Divi’s has several ongoing customer projects and long-term contracts that guide their investments and production schedules.
- Management emphasized the robustness of the pipeline and their readiness to scale capacity as needed, supported by multiple production blocks and available land for future expansion.
Divis Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.8K Cr, net profit ₹751 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Divi's Lab.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare Ltd (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
- Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
- Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Divis Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Divis Laboratories Ltd Q2 FY26 results?
The company has a healthy project pipeline, with multiple projects at different milestones; outcomes expected in next 1-2 years. Divi's Laboratories anticipates positive growth in the next 1-2 years driven by new product launches, especially generics coming off patents, and growth in contract synthesis (CS) business (Pages 9, 16).
What is Divis Laboratories Ltd share price analysis?
Divis Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 75.5 with a market cap of ₹225,038 Cr. Investors should review the full earnings analysis for detailed insights.
Is Divis Laboratories Ltd planning capital expenditure?
Divi's Laboratories is executing three major capex programs focused on new technologies, capacity expansion, and key strategic projects.
Keep Divis Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.